Hepatic venous outflow obstruction: Three similar syndromes

World Journal of Gastroenterology

Volumn 13, Issue 13, 2007, Pages 1912-1927

  Bayraktar, Ulas Darda ^a   Seren, Soley ^b   Bayraktar, Yusuf ^c  

^a INTERFAITH MEDICAL CENTER   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Budd Chiarl syndrome; Congestive hepatopathy; Sinusoidal obstruction syndrome; Veno occlusive disease

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ALTEPLASE; ANTITHROMBIN III; BUSULFAN; CARMUSTINE; CYTOTOXIC AGENT; DEFIBROTIDE; DIURETIC AGENT; GLUTAMINE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PENTOXIFYLLINE; PLACEBO; PROSTAGLANDIN E1; URSODEOXYCHOLIC ACID;

ABDOMINAL CRAMP; ASCITES; BLEEDING; BUDD CHIARI SYNDROME; CENTRAL VEIN; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEPATOPATHY; CONSTRICTIVE PERICARDITIS; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DRUG DOSE TITRATION; DRUG FATALITY; DRUG FEVER; DRUG MECHANISM; HEMOFILTRATION; HEPATOMEGALY; HISTOPATHOLOGY; HOT FLUSH; HUMAN; HYPOTENSION; JAUNDICE; LIVER FIBROSIS; LIVER INJURY; LIVER NECROSIS; LIVER SINUSOID; LIVER TRANSPLANTATION; LIVER VEIN OBSTRUCTION; LIVER VENOOCCLUSIVE DISEASE; LOW DRUG DOSE; NAUSEA; PARACENTESIS; PORTOSYSTEMIC ANASTOMOSIS; REVIEW; SODIUM RESTRICTION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VASOMOTOR DISORDER;

EID: 34248563497     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i13.1912     Document Type: Review

References (187)

1. Lautt WW, Greenway CV. Conceptual review of the hepatic vascular bed. Hepatology 1987; 7: 952-963
2. Rosenberg PM, Friedman LS. The liver in circulatory failure. In: Schiff ER, Sorrell MF, Maddrey WC. Schiff diseases of the liver. 9th ed. Philadelphia: Lippincott Williams & Wilkins, 2004,1327-1340
3. Shulman HM, McDonald GB, Matthews D, Doney KC, Kopecky KJ, Gauvreau. JM, Thomas ED. An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology 1980; 79:1178-1191
4. Tanaka M, Wanless IR. Pathology of the liver in Budd-Chiari syndrome: portal vein thrombosis and the histogenesis of veno-centric cirrhosis, veno-portal cirrhosis, and large regenerative nodules. Hepatology 998; 27: 488-496
5. Arora A, Tandon N, Sharma MP, Acharya SK. Constrictive pericarditis masquerading as Budd-Chiari syndrome. J Clin Gastroenterol 1991; 13: 178-181
6. Sherlock S. The liver in heart failure; relation of anatomical, functional, and circulatory changes. Br Heart J 1951; 13: 273-293
7. Berk PD, Popper H, Krueger GR, Decter J, Herzig G, Graw RG Jr. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation: possible association with graft-versus-host disease. Ann Intern Med 1979; 90: 158-164
8. Fajardo LF, Colby TV. Pathogenesis of veno-occlusive liver disease after radiation. Arch Pathol Lab Med 1980; 104: 584-588
9. King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist 2001; 6: 162-176
10. Tandon BN, Tandon HD, Tandon RK, Narndranathan M, Joshi YK. An epidemic of veno-occlusive disease of liver in central India. Lancet 1976; 2: 271-272
11. Mohabbat O, Younos MS, Merzad AA, Srivastava RN, Sediq GG, Aram GN. An outbreak of hepatic veno-occlusive disease in north-western Afghanistan. Lancet 1976; 2: 269-271
12. Sebagh M, Debette M, Samuel D, Emile JF, Falissard B, Cailliez V, Shouval D, Bismuth H, Reynes M. & quot; Silent & quot; presentation of veno-occlusive disease after liver transplantation as part of the process of cellular rejection with endothelial predilection. Hepatology 1999; 30: 1144-1150
13. Bras G, Jelliffe DB, Stuart KL. Veno-occlusive disease of liver with nonportal type of cirrhosis, occurring in Jamaica. AMA Arch Pathol 1954; 57: 285-300
14. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002; 22: 27-42
15. Carreras E, Bertz H, Arcese W, Vernant JP, Tomas JF, Hagglund H, Bandini G, Esperou H, Russell J, de la Rubia J, Di Girolamo G, Demuynck H, Hartmann O, Clausen J, Ruutu T, Leblond V, Iriondo A, Bosi A, Ben-Bassat I, Koza V, Gratwohl A, Apperley JF. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998; 92: 3599-3604
16. McDonald GB, Hinds MS, Fisher LD, Schoch FIG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267
17. Kumar S, DeLeve LD, Kamath PS, Tefferi A. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc 2003; 78: 589-598
18. Carreras E, Granena A, Navasa M, Bruguera M, Marco V, Sierra J, Tassies MD, Garcia-Pagan JC, Marti JM, Bosch J. On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease. Ann Hematol 1993; 66: 77-80
19. Rio B, Andreu G, Nicod A, Arrago JP, Dutrillaux F, Samama M, Zittoun R. Thrombocytopenia in venocclusive disease after bone marrow transplantation or chemotherapy. Blood 1986; 67: 1773-1776
20. Meresse V, Hartmann O, Vassal G, Benhamou E, Valteau-Couanet D. Brugieres L, Lemerle J. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant 1992; 10: 135-141
21. Ayash LJ, Hunt M, Antman K, Nadler L, Wheeler C, Takvorian T, Elias A, Antin JH, Greenough T, Eder JP. Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin Oncol 1990; 8: 1699-1706
22. Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, McDonald GB. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 11: 1729-1736
23. Frickhofen N, Wiesneth M, Jainta. C, Hertenstein B, Heymer B, Bianchi L, Dienes HP, Koerner K, Bunjes D, Arnold R. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 1994; 83: 1998-2004
24. Strasser SI, Myerson D, Spurgeon CL, Sullivan KM, Storer B, Schoch HG, Kim S, Flowers ME, McDonald GB. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 1999; 29:1893-1899
25. Rozman C, Carreras E, Qian C, Gale RP, Bortin MM, Rowlings PA, Ash RC, Champlin RE, Henslee-Downey PJ, Herzig RH, Hinterberger W, Mein JP, Prentice HG, Reiffers J, Zwaan FE, Horowitz MM. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. Bone Marrow Transplant 1996; 17: 75-80
26. Ertem M, Akar N. Factor V Leiden mutation as a predisposing factor for veno-occlusive disease following BMT. Bone Marrow Transplant 2000; 25: 1110-1111
27. Duggan C, Schmidt M, Lawler M, White B, Cusack S, McCann S, Smith O. The prothrombin gene variant G20210A but not factor V leiden may be associated with veno-occlusive disease following BMT. Bone Marrow Transplant 1999; 24: 693-694
28. Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Alyea EP, Antin JH, Stone RM, Soiffer RJ, DeAngelo DJ. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003; 102: 1578-1582
29. Hagglund H, Remberger M, Klaesson S, Lonnqvist B, Ljungman P, Ringden O. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood 1998; 92: 4568-4572
30. Kalayoglu-Besisik S, Yenerel MN, Caliskan Y, Ozturk S, Besisik F, Sargin D. Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years. Transplant Proc 2005; 37: 2285-2289
31. DeLeve LD. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 1996; 24: 830-837
32. Shulman HM, Hinterberger W. Hepatic veno-occlusive disease-liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 197-214
33. MMcDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-122
34. Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, Vogelsang GB, Sensenbrenner LL, Santos GW, Saral R. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783
35. Shulman HM, Gooley T, Dudley MD, Kofler T, Feldman R, Dwyer U, McDonald GB. Utility of transvenous; liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation 1995; 59: 1015-1079
36. Carreras E, Granena A, Navasa M, Bruguera M, Marco V, Sierra J, Tassies MD, Garcia-Pagan JC, Marti JM, Bosch J. Transjugular liver biopsy in BMT. Bone Marrow Transplant 1993; 11: 21-26
37. Yoshimoto K, Ono N. Okamura T, Sata M. Recent progress in the diagnosis and therapy for veno-occlusive disease of the liver. Leuk Lymphoma 2003; 44: 229-234
38. Salat C, Holler E, Kolb HJ, Reinhardt B, Pihusch R, Wilmanns W, Hiller E. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood 1997; 89: 2184-2188
39. Rio B, Bauduer F, Arrago JP, Zittoun R. N-terminal peptide of type III procollagen: a marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin. Bone Marrow Transplant 1993; 11: 471-472
40. Fried MW, Duncan A, Soroka S, Connaghan DG, Farrand A, Peter J, Strauss RM, Boyer TD, McDonald GB. Serum hyaluronic acid in patients with veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplant 2001; 27: 635-639
41. Strasser SI, McDonald GB. Hepatobiliary complications of hematopoietic cell transplantation. In: Schiff ER, Sorrell MF, Maddrey WC. Schiff's diseases of the liver. 9th ed. Philadelphia: Lippincott Williams & Wilkins, 2004,1635-1658
42. Carreras E. Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol 2000; 64: 281-291
43. DeLeve LD, McCuskey RS, Wang X, Hu. L. McCuskey MK, Epstein RB, Kanel GC. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology 1999; 29: 1779-1791
44. Shulman HM, Gown AM, Nugent DJ. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol 1987; 127: 549-558
45. Sato Y, Asada Y, Hara S, Marutsuka K, Tamura K, Hayashi T, Sumiyoshi A. Hepatic stellate cells (Ito cells) in veno-occlusive disease of the liver after allogeneic bone marrow transplantation. Histopathology 1999; 34: 66-70
46. DeLeve LD, Wang X, Kuhlenkamp JF, Kaplowitz N. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease. Hepatology 1996; 23: 589-599
47. Wang X, Kanel GC, DeLeve LD. Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat. Hepatology 2000; 31: 428-434
48. Srivastava A, Poonkuzhali B, Shaji RV, George B, Mathews V, Chandy M, Krishnamoorthy R. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 2004; 104: 1574-1577
49. Lee JH, Lee KH, Kim S, Lee JS, Kim WK, Park CJ, Chi HS, Kim SH. Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study. Bone Marrow Transplant 1998; 22: 883-888
50. Soiffer RJ, Dear K, Rabinowe SN, Anderson KC, Freedman AS, Murray C, Tarbell NJ, Mauch P, Nadler LM, Ritz J. Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation. Transplantation 1991; 52:1014-1019
51. Ohashi K, Tanabe J, Watanabe R, Tanaka T, Sakamaki H, Maruta A, Okamoto S, Aotsuka N, Saito K, Nishimura M, Oh H, Matsuzaki M, Takahashi S, Yonekura S. The Japanese multicenter open randomized trial of ursocleoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol 2000; 64: 32-38
52. Essell JH, Schroeder MT, Harman GS, Halvorson R, Lew V, Callander N, Snyder M, Lewis SK, Allerton JP, Thompson JM. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 975-981
53. Attal M, Huguet F, Rubie H, Huynh A, Charlet JP, Payen JL, Voigt JJ, Brousset P, Selves J, Muller C. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randon-dzed trial. Blood 1992; 79: 2834-2840
54. Rosenthal J, Sender L, Secola R, Killen R, Millerick M, Murphy L, Cairo MS. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Bone Marrow Transplant 1996; 18: 185-191
55. Marsa-Vila L, Gorin NC, Laporte JP, Labopin M, Dupuy-Montbrun MC, Fouillard L, Isnard F, Najman A. Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation. Eur J Haematol 1991; 47: 346-354
56. Or R, Nagler A, Shpilberg O, Elad S, Naparstek E, Kapelushnik J, Cass Y, Gillis S, Chetrit A, Slavin S, Eldor A. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation 1996; 61: 1067-1071
57. Forrest DL, Thompson K, Dorcas VG, Couban SH, Pierce R. Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study. Bone Marrow Transplant 2003; 31: 1143-1149
58. Or R, Elad S, Shpilberg O, Eldor A. Low molecular weight heparin stimulates megakaryocytopoiesis in bone-marrow transplantation patients. Am J Hematol 1996; 53: 46-48
59. Brown SA, Goringe A, Fegan C, Davies SV, Giddings J, Whittaker JA, Burnett AK, Poynton CH. Parenteral glutamine protects hepatic function during bone marrow transplantation. Bone Marrow Transplant 1998; 22: 281-284
60. Gluckman E, Jolivet L Scrobohaci ML, Devergie A, Traineau R, Bourdeau-Esperou H, Lehn P, Faure P, Drouet L. Use of prostaglandin El for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. Br J Haematol 1990; 74: 277-281
61. Bearman SI, Shen DD, Hinds MS, Hill HA, McDonald GB. A phase I/II study of prostaglandin El for the prevention of hepatic venocclusive disease after bone marrow transplantation. Br J Haematol 1993; 84: 724-730
62. Attal M, Huguet F, Rubie H, Charlet JP, Schlaifer D, Huynh A, Laurent G, Pris J. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial. Blood 1993; 82: 732-736
63. Clift RA, Bianco JA, Appelbaum FR, Buckner CD, Singer JW, Bakke L, Bensinger WL Bowden RA, McDonald GB, Schubert M. A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood 1993; 82: 2025-2030
64. Chalandon Y, Roosnek E, Mermillod B, Newton A, Ozsahin H, Wacker P, Helg C, Chapuis B. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 347-354
65. Versluys B, Bhattacharaya R, Steward C, Cornish J, Oakhill A, Goulden N. Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. Blood 2004; 103: 1968
66. Bearman SI, Shuhart MC, Hinds MS, McDonald GB. Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation. Blood 1992; 80: 2458-2462
67. Leahey AM, Bunin NJ. Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients. Bone Marrow Transplant 1996; 17: 1101-1104
68. Ringden O, Wermberg L, Ericzon BG, Kallman R, Astrom M, Duraj F, Soderdahl G, Tyden G, Groth CG. Alteplase for hepatic veno-occlusive disease after bone marrow transplantation. Lancet 1992; 340: 546-547
69. Hagglund H, Ringden O, Ericzon BG, Duraj F, Ljungman P, Lonnqvist B, Winiarski J, Tyden G. Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator or orthotopic liver transplantation after allogeneic bone marrow transplantation. Transplantation 1996; 62: 1076-1080
70. Bearman SI, Lee JL, Baron AE, McDonald GB. Treatment of hepatic venocclusive disease with recombinant human tissue plasn-dnogen activator and heparin in 42 marrow transplant patients. Blood 1997; 89: 1501-1506
71. Ibrahim RB, Peres E, Dansey R, Abidi MH, Abella EM, Klein J. Anti-thrombin M in the management of hematopoietic stem-cell transplantation-associated toxicity. Ann Pharmacother 2004; 38: 1053-1059
72. Mertens R, Brost H, Granzen B, Nowak-Gottl U. Antithrombin treatment of severe hepatic veno-occlusive disease in children with cancer. Eur J Pediatr 1999; 158 Suppl 3: S154-S158
73. Morris JD, Harris RE, Hashmi R, Sambrano JE, Gruppo RA, Becker AT, Morris CL. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant 1997; 20: 871-878
74. Higashigawa M, Watanabe M, Nishihara H, Tabata N, Azuma E, Ido M, Ito M, Sakurai M. Successful treatment of an infant with veno-occlusive disease developed after allogeneic bone marrow transplantation by tissue plasminogen activator, heparin and prostaglandin El. Leuk Res 1995; 19: 477-480
75. Ibrahim A, Pico JL, Maraninchi D, Zambon E, Attal M, Brault P, Tilly H, Blaise D, Hayat M. Hepatic veno-occlusive disease following bone marrow transplantation treated by prostaglandin El. Bone Marrow Transplant 1991; 7 Suppl 2: 53
76. Schlegel PG, Haber HP, Beck J, Krumpelmann S, Handgretinger R, Bader P, Bierings M, Niethammer D, Klingebiel T. Hepatic veno-occlusive disease in pediatric stem cell recipients: successful treatment with continuous infusion of prostaglandin El and low-dose heparin. Ann Hematol 1998; 76: 37-41
77. Tefferi A, Kumar S, Wolf RC, Lacy MQ Inwards DJ, Gloor JM, Albright RC, Kamath PS, Litzow MR. Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 997-999
78. Ringden O, Remberger M, Lehmann S, Hentschke P, Mattsson J, Klaesson S, Aschan J. N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2000; 25: 993-996
79. Goringe AP, Brown S, O'Callaghan U, Rees J, Jebb S, Elia M, Poynton CH. Glutamine and vitamin E in the treatment of hepatic veno-occlusive disease following high-dose chemotherapy. Bone Marrow Transplant 1998; 21: 829-832
80. Nattakom TV, Charlton A, Wilmore DW. Use of vitamin E and glutamine in the successful treatment of severe veno-occlusive disease following bone marrow transplantation. Nutr Clin Pract 1995; 10: 16-18
81. Palmer KJ, Goa KL. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs 1993; 45: 259-294
82. Bianchi G, Barone D, Lanzarotti E, Tettamanti R, Porta R, Moltrasio D, Cedro A, Salvetti L, Mantovani M, Prino G. Defibroticle, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist. Eur J Pharmacol 1993; 238: 327-334
83. Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, Elias AD, Antin JH, Soiffer R, Spitzer T, Avigan D, Bearman SI, Martin PL, Kurtzberg J, Vredenburgh J, Chen AR, Arai S, Vogelsang G, McDonald GB, Guinan EC. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002; 100: 4337-4343
84. Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C, Neurneister P, Finazzi G, lacobelli M, Bowyer K, Prentice HG, Barbui T. Defibroticle for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000; 111: 1122-1129
85. Fried MW, Connaghan DG, Sharma S, Martin LG, Devine S, Holland K, Zuckerman A, Kaufman S, Wingard J, Boyer TD. Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation. Hepatology 1996; 24: 588-591
86. Azoulay D, Castaing D, Lemoine A, Hargreaves GM, Bismuth H. Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation. Bone Marrow Transplant 2000; 25: 987-992
87. Annaloro C, Robbiolo L, Pozzoli E, lbatici A, Nicolini A, Salerno F, Deliliers GL. Four-year survival after trans-jugular intrahepatic porto-systemic shunt for veno-occlusive disease following autologous bone marrow transplantation. Leuk Lymphoma 2004; 45: 1485-1487
88. Nimer SD, Milewicz AL, Champlin RE, Busuttil RW. Successful treatment of hepatic venoocclusive disease in a bone marrow transplant patient with orthotopic liver transplantation. Transplantation 1990; 49: 819-821
89. Rapoport AP, Doyle HR, Starzl T, Rowe JM, Doeblin T, DiPersio JF. Orthotopic liver transplantation for life-threatening veno-occlusive disease of the liver after allogeneic bone marrow transplant. Bone Marrow Transplant 1991; 8: 421-424
90. Kim ID, Egawa H, Marui Y, Kaihara S, Haga H, Lin YW, Kudoh K, Kiuchi T, Uemoto S, Tanaka K. A successful liver transplantation for refractory hepatic veno-occlusive disease originating from cord blood transplantation. Am J Transplant 2002; 2: 796-800
91. Okuda K, Kage M, Shrestha SM. Proposal of a new nomenclature for Budd-Chiari syndrome: hepatic vein thrombosis versus thrombosis of the inferior vena cava at its hepatic portion. Hepatology 1998; 28: 1191-1198
92. Bogin V, Marcos A, Shaw-Stiffel T. Budd-Chiari syndrome: in evolution. Eur J Gastroenterol Hepatol 2005; 17: 33-35
93. Valla DC. Hepatic vein thrombosis (Budd-Chiari syndrome). Semin Liver Dis 2002; 22: 5-14
94. Valla D, Casadevall N, Lacombe C, Varet B, Goldwasser E, Franco D, Maillard JN, Pariente EA, Leporrier M, Rueff B. Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med 1985; 103: 329-334
95. Denninger MH, Chait Y, Casadevall N, Hillaire S, Guillin MC, Bezeaud A, Erlinger S, Briere J, Valla D. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000; 31: 587-591
96. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333: 1253-1258
97. Socie G, Mary JY, de Gramont A, Rio B, Leporrier M, Rose C, Heudier P, Rochant H, Cahn JY, Gluckman E. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet 1996; 349: 573-577
98. Deltenre P, Denninger MH, Hillaire S, Guillin MC, Casadevall N, Briere J, ErlingeT S, Valla DC. Factor V Leiden related Budd-Chiari syndrome. Gut 2001; 48: 264-268
99. Mahmoud AE, Elias E, Beauchamp N, Wilde JT. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut 1997; 40: 798-800
100. Valla DC. The diagnosis and management of the Budd-Chiari syndrome: consensus and controversies. Hepatology 2003; 38: 793-803
101. Okuda K. Inferior vena cava thrombosis at its hepatic portion (obliterative hepatocavopathy). Semin Liver Dis 2002; 22: 15-26
102. Simson IW. Membranous obstruction of the inferior vena cava and hepatocellular carcinoma in South Africa. Gastroenterology 1982; 82: 171-178
103. Bayraktar Y, Egesel T, Saglam F, Balkanci F, Van Thiel DH. Does hepatic vein outflow obstruction contribute to the pathogenesis of hepatocellular carcinoma? J Clin Gastroenterol 1998; 27: 67-71
104. Harmanci O, Buyukasik Y, Kirazli S, Balkanci F, Bayraktar Y. Does endothelium agree with the concept of idiopathic hepatic vessel thrombosis? World J Gastroenterol 2006; 12: 1273-1277
105. Henrion J. Ischemia/reperfusion injury of the liver: pathophysiologic hypotheses and potential relevance to human hypoxic hepatitis. Acta Gastroenterol Belg 2000; 63: 336-347
106. Olzinski AT, Sanyal AJ. Treating Budd-Chiari Syndrome: making rational choices from a myriad of options. J Clin Gastroenterol 2000; 30: 155-161
107. Tavill AS, Wood EJ, Kreel L, Jones EA, Gregory M, Sherlock S. The Budd-Chiari syndrome; correlation between hepatic scintigraphy and the clinical, radiological, and pathological findings in nineteen cases of hepatic venous outflow obstruction. Gastroenterology 1975; 68: 509-518
108. Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 1990; 11: 787-797
109. Cazals-Hatem D, Vilgrain V, Genin P, Denninger N4H, Durand F, Belghiti J, Valla D, Degott C. Arterial and portal circulation and parenchymal changes in Budd-Chiari syndrome: a study in 17 explanted livers. Hepatology 2003; 37: 510-519
110. Parker RG. Occlusion of the hepatic veins in man. Medicine (Baltimore) 1959; 38: 369-402
111. Mahmoud AE, Mendoza A, Meshikhes AN, Olliff S, West R, Neuberger J, Buckels J, Wilde J, Elias E. Clinical spectrum, investigations and treatment of Budd-Chiari syndrome. QJM 1996; 89: 37-43
112. Murad SD, Valla DC, de Groen PC, Zeitoun G, Hopmans JA, Haagsma EB, van Hoek B, Hansen BE, Rosendaal FR, Janssen HL. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 2004; 39: 500-508
113. Hadengue A, Poliquin M, Vilgrain V, Belghiti J, Degott C, Erlinger S, Benhamou JP. The changing scene of hepatic vein thrombosis: recognition of asymptomatic cases. Gastroenterology 1994; 106: 1042-1047
114. Dilawari JB, Bambery P, Chawla Y, Kaur U, Bhusnurmath SR, Malhotra HS, Sood GK, Mitra SK, Khanna SK, Walia BS. Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature. Medicine (Baltimore) 1994; 73: 21-36
115. De BK, Sen S, Biswas PK, Mandal SK, Das D, Das U, Guru S, Bandyopadhyay K. Occurrence of hepatopulmonary syndrome in Budd-Chiari syndrome and the role of venous decompression. Gastroenterology 2002; 122: 897-903
116. Singh V, Sinha SK, Nain CK, Bambery P, Kaur U, Verma S, Chawla YK, Singh K. Budd-Chiari syndrome: our experience of 71 patients. J Gastroenterol Hepatol 2000; 15: 550-554
117. Kage M, Arakawa M, Kojiro M, Okuda K. Histopathology of membranous obstruction of the inferior vena cava in the Budd-Chiari syndrome. Gastroenterology 1992; 102: 2081-2090
118. Shrestha SM, Okuda K Uchida T, Mahaijan KG, Shrestha S, Joshi BL, Larsson S, Vaidya Y. Endemicity and clinical picture of liver disease due to obstruction of the hepatic portion of the inferior vena cava in Nepal. J Gastroenterol Hepatol 1996; 11: 170-179
119. Bayraktar Y, Harmanci O. Etiology and consequences of thrombosis in abdominal vessels. World J Gastroenterol 2006; 12: 1165-1174
120. Brinson RR, Curtis WD, Schuman BM, Mills LR. Recovery from hepatic vein thrombosis (Budd-Chiari syndrome) complicating ulcerative colitis. Dig Dis Sci 1988; 33: 1615-1620
121. Zeitoun G, Escolano S, Hadengue A, Azar N, El Younsi M, Mallet A, Boudet MJ, Hay JM, Erlinger S, Benhamou JP, Belghiti J, Valla D. Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology 1999; 30: 84-89
122. Tang TJ, Batts KP, de Groen PC, van Hoek B, Haagsma EB, Hop WC, Janssen HL. The prognostic value of histology in the assessment of patients with Budd-Chiari syndrome. J Hepatol 2001; 35: 338-343
123. Henderson JM, Warren WD, Millikan WJ Jr, Galloway JR, Kawasaki S, Stahl RL, Hertzler G. Surgical options, hematologic evaluation, and pathologic changes in Budd-Chiari syndrome. Am J Surg 1990; 159: 41-48; discussion 48-50
124. Okuda H, Yamagata H, Obata H, lwata H, Sasaki R, Imai F, Okudaira M, Ohbu Mi Okuda K. Epiden-dological and clinical features of Budd-Chiari syndrome in Japan. J Hepatol 1995; 22: 1-9
125. Murad SD, Valla DC, de Groen PC, Zeitoun G, Haagsma EB, Kuipers EJ, Janssen HL. Pathogenesis and treatment of Budd-Chiari syndrome combined with portal vein thrombosis. Am J Gastroenterol 2006; 101: 83-90
126. Wadhawan M, Kumar N. Budd-Chiari syndrome. Trop Gastroenterol 2003; 24: 3-7
127. Bolondi L, Gaiani S, Li Bassi S, Zironi G, Bonino F, Brunetto M, Barbara L. Diagnosis of Budd-Chiari syndrome by pulsed Doppler ultrasound. Gastroenterology 1991; 100: 1324-1331
128. Gupta S, Barter S, Phillips GW, Gibson RN, Hodgson HJ. Comparison of ultrasonography, computed tomography and 99mTc liver scan in diagnosis of Budd-Chiari syndrome. Gut 1987; 28: 242-247
129. Millener P, Grant EG, Rose S, Duerinckx A, Schiller VL, Tessler FN, Perrella RR, Ragavendra N. Color Doppler imaging findings in patients with Budd-Chiari syndrome: correlation with venographic findings. AIR Am J Roentgenol 1993; 161: 307-312
130. Ralls PW, Johnson MB, Radin DR, Boswell WD Jr, Lee KP, Halls JM. Budd-Chiari syndrome: detection with color Doppler sonography. AJR Am J Roentgenol 1992; 159: 113-116
131. Lim JH, Park JH, Auh YH. Membranous obstruction of the inferior vena cava: comparison of findings at sonography, CT, and venography. AJR Am J Roentgenol 1992; 159: 515-520
132. Mathieu D, Vasile N, Menu Y, Van Beers B, Lorphelin JM, Pringot J. Budd-Chiari syndrome: dynamic CT. Radiology 1997; 65: 409-413
133. Stark DD, Hahn PF, Trey C, Clouse ME, Ferrucci JT Jr. MRI of the Budd-Chiari syndrome. AIR Am J Roentgenol 1986; 146: 1141-1148
134. Soyer P, Rabenandrasana A, Barge J, Laissy JP, Zeitoun G, Hay JM, Levesque M. MRI of Budd-Chiari syndrome. Abdom Imaging 1994; 19: 325-329
135. Mitchell MC, Boitnott JK, Kaufman S, Cameron JL, Maddrey WC. Budd-Chiari syndrome: etiology, diagnosis and management. Medicine (Baltimore) 1982; 61: 199-218
136. Wang ZG, Jones RS. Budd-Chiari syndrome. Curr Probl Surg 1996; 33: 83-211
137. Millikan WJ Jr, Henderson JM, Sewell CW, Guyton RA, Potts JR 3rd, Cranford CA Jr, Cramer AR, Galambos JT, Warren WD. Approach to the spectrum of Budd-Chiari syndrome: which patients require portal decompression? Am J Surg 1985; 149: 167-176
138. Brearley S, Hawker PC, Dykes PW, Keighley MR. A lethal complication of peripheral vein vasopressin infusion. Hepatogastroenterology 1985; 32: 224-225
139. Menon KV, Shah V, Kamath PS. The Budd-Chiari syndrome. N Engl J Med 2004; 350: 578-585
140. Frank JW, Kamath PS, Stanson AW. Budd-Chiari syndrome: early intervention with angioplasty and thrombolytic therapy. Mayo Clin Proc 1994; 69: 877-881
141. Raju GS, Felver M, Olin JW, Satti SD. Thrombolysis for acute Budd-Chiari syndrome: case report and literature review. Am J Gastroenterol 1996; 91: 1262-1263
142. Sparano J, Chang J, Trasi S, Bonanno C. Treatment of the udd-Chiari syndrome with percutaneous transluminal angioplasty. Case report and review of the literature. Am J Med 1987; 82: 821-828
143. Xu K, He FX, Zhang HG, Zhang XT, Han MJ, Wang CR, Kaneko M, Takahashi M, Okawada T. Budd-Chiari syndrome caused by obstruction of the hepatic inferior vena cava: immediate and 2-year treatment results of transluminal angioplasty and metallic stent placement. Cardiovasc Intervent Radiol 1996; 19: 32-36
144. Zhang CQ, Fu LN, Xu L, Zhang GQ Jia T, Liu JY, Qin CY, Zhu JR. Long-term effect of stent placement in 115 patients with Budd-Chiari syndrome. World J Gastroenterol 2003; 9: 2587-2591
145. Pisani-Ceretti A, Intra M, Prestipino F, Ballarini C, Cordovana A, Santambrogio R, Spina GP. Surgical and radiologic treatment of primary Budd-Chiari syndrome. World J Surg 1998; 22: 48-53; discussion 53-54
146. Witte AM, Kool LJ, Veenendaal R, Lamers CB, van Hoek B. Hepatic vein stenting for Budd-Chiari syndrome. Am J Gastroenterol 1997; 92: 498-501
147. Janssen HL, Garcia-Pagan JC, Elias E, Mentha G, Hadengue A, Valla DC. Budd-Chiari syndrome: a review by an expert panel. J Hepatol 2003; 38: 364-371
148. Ryu RK, Durham JD, Krysl J, Shrestha R, Shrestha R, Everson GT, Stephens J, Kam I, Wachs M, Kumpe DA. Role of TIPS as a bridge to hepatic transplantation in Budd-Chiari syndrome. J Vasc Interv Radiol 1999; 10: 799-805
149. Ganger DR, Klapman JB, McDonald V, Matalon TA, Kaur S, Rosenblate H, Kane R, Saker M, Jensen DM. Transjugular intrahepatic portosystemic shunt (TIPS) for Budd-Chiari syndrome or portal vein thrombosis: review of indications and problems. Am J Gastroenterol 1999; 94: 603-608
150. Senzolo M, Cholongitas EC, Patch D, Burroughs AK. Update on the classification, assessment of prognosis and therapy of Budd-Chiari syndrome. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 182-190
151. Mancuso A, Fung K, Mela M, Tibballs J, Watkinson A, Burroughs AK, Patch D. TIPS for acute and chronic Budd-Chiari syndrome: a single-centre experience. J Hepatol 2003; 38: 751-754
152. Mancuso A, Watkinson A, Tibballs J, Patch D, Burroughs AK. Budd-Chiari syndrome with portal, splenic, and superior mesenteric vein thrombosis treated with TIPS: who dares wins. Gut 2003; 52: 438
153. Perello A, Garcia-Pagan JC, Gilabert R, Suarez Y, Moitinho E, Cervantes F, Reverter JC, Escorsell A, Bosch J, Rodes J. TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology 2002; 35: 132-139
154. Hernandez-Guerra M, Turnes J, Rubinstein P, Olliff S, Elias E, Bosch J, Garcia-Pagan JC. PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology 2004; 40: 1197-1202.
155. Slakey DP, Klein AS, Venbrux AC, Cameron JL. Budd-Chiari syndrome: current management options. Ann Surg 2001; 233: 522-527
156. Orloff MJ, Daily PO, Orloff SL, Girard B, Orloff MS. A 27-year experience with surgical treatment of Budd-Chiari syndrome. Ann Surg 2000; 232: 340-352
157. Ringe B, Lang H, Oldhafer KJ, Gebel M, Flemming P, Georgii A, Borst HG, Pichlmayr R. Which is the best surgery for Budd-Chiari syndrome: venous decompression or liver transplantation? A single-center experience with 50 patients. Hepatology 1995; 21: 1337-1344
158. Eid A, Rahamimov R, Ilan Y, Tur-Kaspa R, Berlatzky Y. Cavoatrial shunt: a graft salvage procedure for suprahepatic caval anastomosis obstruction after liver transplantation. Liver Transpl Surg 1998; 4: 239-240
159. Klein AS, Cameron JL. Diagnosis and management of the Budd-Chiari syndrome. Am J Surg 1990; 160: 128-133
160. Chang CH, Lee MC, Shieh MJ, Chang JP, Lin PJ. Transatrial membranotomy for Budd-Chiari syndrome. Ann Morac Surg 1989; 48: 409-412
161. Senning A. Transcaval posterocranial resection of the liver as treatment of the Budd-Chiari syndrome. World J Surg 1983; 7: 632-640
162. Jamieson NV, Williams R, Calne RY. Liver transplantation for Budd-Chiari syndrome, 1976-1990. Ann Chir 1991; 45: 362-365
163. Srinivasan P, Rela M, Prachalias A, Muiesan P, Portmann B, Mufti GJ, Pagliuca A, O'Grady J, Heaton N. Liver transplantation for Budd-Chiari syndrome. Transplantation 2002; 73: 973-977
164. Campbell DA Jr, Rolles K, Jamieson N, O'Grady J, Wight D, Williams R, Calne R. Hepatic transplantation with perioperative and long term anticoagulation as treatment for Budd-Chiari syndrome. Surg Gynecol Obstet 1988; 166: 511-518
165. Moussavian SN, Dincsoy HP, Goodman S, Helm RA, Bozian RC. Severe hyperbilirubinemia and coma in chronic congestive heart failure. Dig Dis Sci 1982; 27: 175-180
166. Logan RG, Mowry FM, Judge RD. Cardiac failure simulating viral hepatitis. Three cases with serum transaminase levels above 1000. Ann Intern Med 1962; 56: 784-788
167. Cohen JA, Kaplan MM. Left-sided heart failure presenting as hepatitis. Gastroenterology 1978; 74: 583-587
168. Nouel O, Henrion J, Bemuau J, Degott C, Rueff B, Benhamou JP. Fulminant hepatic failure due to transient circulatory failure in patients with chronic heart disease. Dig Dis Sci 1980; 25: 49-52
169. Kisloff B, Schaffer G. Fuhninant hepatic failure secondary to congestive heart failure. Am J Dig Dis 1976; 21: 895-900
170. Dunn GD, Hayes P, Breen KJ, Schenker S. The liver in congestive heart failure: a review. Am J Med Sci 1973; 265: 174-189
171. Richman SM, Delamn AJ, Grob D. Alterations in indices of liver function in congestive heart failure with particular reference to serum enzymes. Am J Med 1961; 30: 211-225
172. Jafri SM. Hypercoagulability in heart failure. Semin Thromb Hemost 1997; 23: 543-545
173. Bessman AN, Evans JM. The blood ammonia in congestive heart failure. Am Heart 11955; 50: 715-719
174. Lowe MD, Harcombe AA, Grace AA, Petch MC. Lesson of the week: restrictive-constrictive heart failure masquerading as liver disease. BMJ 1999; 318: 585-586
175. Denis C, De Kerguennec C, Bernuau J, Beauvais F, Cohen Solal A. Acute hypoxic hepatitis ('liver shock'): still a frequently overlooked cardiological diagnosis. Eur J Heart Fail 2004; 6: 561-565
176. Runyon BA. Cardiac ascites: a characterization. J Clin Gastroenterol 1988; 10: 410-412
177. Naschitz JE, Slobodin G, Lewis RJ, Zuckerman E, Yeshurun D. Heart diseases affecting the liver and liver diseases affecting the heart. Am Heart J 2000; 140: 111-120
178. Ho SS, Brown R, Fitzgibbon B. Hepatocellular carcinoma with cardiac cirrhosis. Med J Aust 1990; 152: 553-554
179. Cameron J, Oesterle SN, Baldwin JC, Hancock EW. The etiologic spectrum of constrictive pericarditis. Am Heart J 1987; 113: 354-360
180. Ling LH, Oh JK, Schaff HV, Danielson GK, Mahoney DW, Seward JB, Tajik AJ. Constrictive pericarditis in the modem era: evolving clinical spectrum and impact on outcome after pericardiectomy. Circulation 1999; 100: 1380-1386
181. Bertog SC, Thambidorai SK, Parakh K, Schoenhagen P, Ozduran V, Houghtaling PL, Lytle BW, Blackstone EH, Lauer MS, Klein AL. Constrictive pericarditis: etiology and cause-specific survival after pericardiectomy. J Am Coll Cardiol 2004; 43: 1445-1452
182. Marshall JB, Pola L. Chylous ascites secondary to constrictive pericarditis. A discussion of pathophysiologic mechanisms. Dig Dis Sci 1982; 27: 84-87
183. Riza Altiparmak M, Avsar S, Yanik S. Chylous ascites and chylothorax due to constrictive pericarditis in a patient undergoing haemodialysis. Neth J Med 2004; 62: 59-61
184. Solano FX Jr, Young E, Talamo TS, Dekker A. Constrictive pericarditis mimicking Budd-Chiari syndrome. Am J Med 1986; 80: 113-115
185. Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, Douglas PS, Faxon DP, Gillam LD, Kimball TR, Kussmaul WG, Pearlman AS, Philbrick JT, Rakowski H, Thys DM, Antman EM, Smith SC Jr, Alpert JS, Gregoratos G, Anderson JL, Hiratzka LF, Hunt SA, Fuster V, Jacobs AK, Gibbons RJ, Russell RO. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003; 108: 1146-1162
186. Talreja DR, Edwards WD, Danielson GK, Schaff HV, Tajik AJ, Tazelaar HD, Breen JF, Oh JK. Constrictive pericarditis in 26 patients with histologically normal pericardial thickness. Circulation 2003; 108: 1852-1857
187. Troughton RW, Asher CR, Klein AL. Pericarditis. Lancet 2004; 363: 717-727